Replies to post #799050 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

NWBO 2024 10K

https://www.otcmarkets.com/filing/html?id=18330703&guid=66b-kWEDbPruQOh#NWBO-20241231X10K_HTM_ITEM7

As previously reported, we have been developing a manufacturing facility in Sawston, U.K. The Sawston facility contains a total of 88,345 square feet on two floors. The initial production capacity comprises two manufacturing suites, occupying approximately 4,400 square feet on the ground floor. These two suites, together with some additional support and storage space, have anticipated potential capacity to produce dendritic cell vaccines for about 40 to 45 patients per month, or approximately 450 to 500 patients annually. The buildout of Phases 1A and 1B of the facility have been completed. We also continue to conduct activities in the GMP (clean room) facility in London.

So we're looking at ~1000 patients a year initially with the buildout of a grade C Lab.

[Slave1]

Everything being debated here becomes clear once you line up the actual evidence. The 40–45 patients per month figure from the 10-K was never a fantasy number. It came directly from the 2 manual Grade B suites at Sawston, and it is the same figure Dr. Bosch presented at ASCO 2022. In that talk, he explicitly stated that Sawston, in its partially built state, could manufacture up to 50 treatments per month in 2 cleanrooms.

His slide showing the ability to scale to 1,000 patients per month was not describing current output. It was presenting the long-term ceiling of the Sawston facility when its full build-out and automation phases (including Eden) are completed. That is exactly what the recent press release describes: construction of the first Grade C manufacturing suite, the Eden-dedicated block designed for high-throughput parallel automation. It is not the first instance of Grade C capability.

Advent already had operational Grade C cleanrooms long before this announcement, which is why SOW-8 could be completed. APS and PPQ cannot be performed in theoretical spaces or rooms under construction, they require functioning Grade C/B/A GMP environments, validated and inspected. This is independently confirmed by Advent’s MHRA manufacturing licenses, the GMP Group qualification report, and multiple Cell & Gene Therapy Catapult surveys. Catapult only lists operational MHRA-verified cleanrooms, and Advent appears in 2022, 2023, 2024, 2025, and 2026 with defined availability percentages.


The new Grade C suite in the press release is simply the physical build-out of the scale-out phase Bosch described in 2022. It represents the Eden expansion zone designed to reach the 1,000-patient-per-month ceiling. The numbers do not conflict. They refer to distinct pieces of the same roadmap: the current validated manual capacity demonstrated by SOW-8, and the future automated commercial capacity now under construction.

[brooktrail1933]

No, they are not fantasy.
Bosch himself gave these approximate numbers a couple of years ago at ASCO.